/
MBRX
$3.57+$0.30 (+9.17%)live
Held · Bookmarked
0 · 0
portfolios · users
Avg position size
—
of holders' portfolios
13F filers
0
institutions
Market cap
$17.4M
5M shares
52-week range
$1.79 – $24.00
8% from low
Sector
PHARMACEUTICAL PREPARATIONS
Exchange
NASDAQ
CS
Borrow rate
223.66%
Hard to borrow
Price (6 mo)
Loading chart…
Change$-1342.68
Valuation
Financials
Loading chart…
Click rows below (any statement) to add/remove series. Selection stays as you switch tabs.
| 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | |
|---|---|---|---|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Cost of revenue | $68.0K | $185.0K | $0 | $0 | $0 | $0 | $0 | $90.0K |
| Gross profit | −$68.0K | −$185.0K | $0 | $0 | $0 | $0 | $0 | −$90.0K |
| Gross margin | — | — | — | — | — | — | — | — |
| R&D | $9.7M | $11.0M | $12.8M | $14.4M | $19.0M | $19.5M | $17.7M | $15.9M |
| Operating income | −$15.0M | −$17.5M | −$19.7M | −$23.0M | −$30.6M | −$29.6M | −$26.6M | −$25.1M |
| EBITDA | −$15.0M | −$13.2M | −$19.5M | −$15.7M | −$28.9M | −$29.6M | −$21.6M | −$33.5M |
| Net income | −$11.9M | −$13.2M | −$17.4M | −$15.9M | −$29.0M | −$29.8M | −$21.8M | −$33.6M |
| Net margin | — | — | — | — | — | — | — | — |
| EPS (diluted) | -1031.54 | -729.63 | -661.00 | -221.77 | -380.51 | -376.71 | -189.14 | -28.42 |
Annual figures · source: Financial Modeling Prep
Analyst estimates (consensus)
| Year | Est. revenue | Est. EPS | EPS range | # Analysts |
|---|---|---|---|---|
| 2026 | $71M | $-5.11 | $-5.60–$-4.61 | 1 |
| 2027 | $42M | $-3.84 | $-4.41–$-3.26 | 2 |
| 2028 | $87M | $-3.56 | $-4.83–$-2.28 | 2 |
| 2029 | $52M | $0.96 | $0.96–$0.96 | 1 |
Forward consensus · source: Financial Modeling Prep
DCF fair valuemodel estimate
Intrinsic value
$4.55
Price
$3.57
Implied upside
+27%
Peer comparison
Moleculin Biotech, Inc.
Moleculin Biotech Inc is a late-stage pharmaceutical development company currently evaluating Annamycin, also known as L-Annamycin and by its generic name naxtarubicin. The company has two additional portfolios of technologies for hard-to-treat cancers and viruses with clinical and preclinical research funded by investigators at academic institutions. The Company operates in one reportable segment, which is the development and commercialization of drug products.
www.moleculin.com- Employees
- 17
- IPO / List date
- Jun 2, 2016
- HQ
- HOUSTON, TX
Held by traders on TradeandTell
No one on the platform currently holds MBRX.
Super investors & insiders
Institutions holding (13F)
No tracked institution reports a position in MBRX as of their last filing.
Insider activity (SEC Form 4)
Stock splits
| Execution date | Ratio |
|---|---|
| 2025-12-01 | 1-for-25reverse |
| 2024-03-22 | 1-for-15reverse |
| 2021-02-01 | 1-for-6reverse |
Recent trades on TradeandTell
No one on the platform has traded MBRX yet.
